Prostate Cancer Update, Issue 1, 2020 (Audio Program)


Interview with Maha Hussain, MD, FACP, FASCO

Track 1: Case: A man in his early 60s with de novo oligometastatic prostate cancer (PC) receives an LHRH agonist and abiraterone/prednisone
Track 2: Effect of preoperative hormonal therapy on shrinkage of the primary tumor
Track 3: Benefit of local therapy in patients with metastatic PC (mPC) and low disease burden; surgery versus radiation therapy in the local management of PC
Track 4: Rationale for adding secondary hormonal therapy or chemotherapy to androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive PC (mHSPC)
Track 5: Results from the CHAARTED, GETUG-AFU15 and STAMPEDE trials establishing the efficacy of docetaxel in combination with ADT for mHSPC
Track 6: Efficacy of secondary hormonal therapy in combination with ADT for mHSPC
Track 7: Risks and benefits with secondary hormone therapy versus chemotherapy in combination with ADT for mHSPC
Track 8: Tolerability of apalutamide versus enzalutamide
Track 9: FDA breakthrough therapy designations for the PARP inhibitors olaparib, rucaparib and niraparib for metastatic castration-resistant PC (mCRPC)
Track 10: Case: A man in his late 60s with mCRPC and a germline BRCA2 mutation receives olaparib with abiraterone/prednisone as first-line therapy on the NU 16U05 clinical trial
Track 11: NU 16U05: A Phase II trial of olaparib or abiraterone alone or in combination as first-line therapy for patients with mCRPC and DNA repair defects
Track 12: Spectrum of genetic alterations in PC
Track 13: Genetic testing for patients with PC; somatic and germline testing for BRCA mutations
Track 14: Rationale for cotargeting the androgen receptor and DNA repair pathways
Track 15: Design and eligibility for the PROfound study evaluating olaparib versus enzalutamide or abiraterone in patients with mCRPC and homologous recombination repair gene alterations who experienced disease progression on prior hormonal therapy
Track 16: Results of the PROfound study; improvement in radiographic progression-free survival and overall response rate with olaparib for men with mCRPC
Track 17: Activity of abiraterone or enzalutamide for men with mCRPC in the second- or later-line setting
Track 18: Duration of response to olaparib, rucaparib and niraparib in PC
Track 19: Potential benefit with a PARP inhibitor in combination with secondary hormonal treatment versus either therapy alone in the up-front setting for patients with mCRPC and DNA repair defects
Track 20: Role of platinum-based chemotherapy for patients with PC and DNA repair defects
Track 21: Perspective on the potential role of olaparib, rucaparib and niraparib as maintenance therapy for patients with mPC and BRCA mutations
Track 22: Clinical implications of the PROfound study results for the future use of olaparib for patients with mCRPC and DNA repair defects
Track 23: Emerging data with olaparib, rucaparib and niraparib for mCRPC
Track 24: Molecular profiling for patients with PC
Track 25: Optimal testing platform for genetic assessment
Track 26: Results from a survey of medical oncologists regarding genetic testing in practice for patients with PC
Track 27: Assessment of MSI status and NTRK fusions in practice

Interview with Karim Fizazi, MD, PhD

Track 1: Case: A man in his early 70s with nonmetastatic CRPC receives darolutamide in combination with ADT on the ARAMIS trial
Track 2: Effect of PSA doubling time on prognosis of patients with nonmetastatic CRPC
Track 3: Results of the Phase III PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic CRPC
Track 4: Tolerability of enzalutamide, apalutamide and darolutamide
Track 5: Activity and side-effect profile of darolutamide for nonmetastatic CRPC
Track 6: Approaches to preventing bone loss in men receiving ADT
Track 7: Optimal integration of radium-223 into current mCRPC treatment algorithms
Track 8: Efficacy and safety with the combination of radium-223 and abiraterone or enzalutamide for mCRPC
Track 9: Selection and sequencing of therapy for patients with mCRPC; role of enzalutamide for patients who experience disease relapse on abiraterone and vice versa
Track 10: Results of the CARD study: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent
Track 11: Role of AR-V7 in clinical decision-making for patients with disease progression on secondary hormonal therapy
Track 12: Diagnosis and incidence of metastasis in men presenting with HSPC
Track 13: STAMPEDE: Radiation therapy to the primary tumor improves survival for the subgroup of patients with newly diagnosed mPC and low metastatic burden
Track 14: Efficacy of chemotherapy or secondary hormonal therapy in combination with ADT for patients with mHSPC
Track 15: Activity of antiandrogens for patients with PC
Track 16: Role of taxanes in the management of PC; comparison of the efficacy and tolerability of cabazitaxel versus docetaxel
Track 17: Germline and somatic testing for patients with mPC
Track 18: Case: A man in his late 70s with mCRPC and a germline BRCA2 mutation achieves a good response to a PARP inhibitor on a clinical trial
Track 19: Efficacy and tolerability of olaparib, rucaparib and niraparib in patients with mPC
Track 20: Activity of platinum-based chemotherapy for patients with mPC and BRCA mutations
Track 21: Potential benefit of PARP inhibitors in patients with PC and alternative DNA damage repair alterations (eg, ATM, CDK12); results from the PROfound trial
 
FACULTY
 
Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois
 
Karim Fizazi, MD, PhD
Department of Cancer Medicine
GETUG President
Institut Gustave Roussy
Professor in Oncology
University of Paris-Sud
Villejuif
Paris, France
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida